Oncotarget Unveils New Findings on Alzheimers and PTC

Alzheimer’s disease (AD), marked by severe memory loss is a deadly degenerative disease affecting the nerves. Concerns are high on its rapid spread among vast sections of the global population.

The external features of AD manifest as progressive loss of cognitive and motor activities and a gradual slowing of language skills with unusual hardship in identifying persons and objects.

This neural disease stems from the increased accumulation of β amyloid peptide (Aβ) and hyperphosphorylated Tau protein depositing as plaques in the nervous system. Follow Oncotarget on Twitter.

Alzheimer’s and Obesity

Rough estimates suggest that 35 million people are affected by the AD, and the number is increasing. Scientists are curious to trace any link between obesity that is rampant in developed countries and the rapid spread of AD.

The malaise of obesity has gripped the developed world. In simple terms, obesity might be a common nutritional disorder, but it is a severe health hazard impinging on cognitive abilities.

Many studies have linked obesity to diminishing cognitive performance and dipping brain volumes. They further lead to severe cognitive decline including AD if patients are obese and afflicted with other metabolic diseases. Download output styles at Endnote.com

The risk of the AD is high with patients with Type 2 Diabetes (T2D) according to Rotterdam studies. However, no mechanism is in sight that links obesity and AD. Also, no molecular system has connected obesity’s relation with brain deviation appearing with the AD.

Among the factors contributing to obesity, a high dose of APP in adipose tissue and high incidence of Aβ in plasma are significant which also step up high insulin resistance. Some studies have attributed obesity to causing T2D and insulin resistance.

New Therapy for PTC Cancer

For a cancer patient, the severest shock will be to learn that the cancer is drug-resistant and becoming incurable.

This dilemma is most acute among papillary thyroid carcinoma (PTC) patients where the drug resistance is appalling. As a frequent thyroid cancer, the drug vemurafenib treats PTC.

Now there is good news for PTC patients. Findings by a Harvard Medical School team says palbociclib, an FDA-approved drug that treats breast cancer can check the drug resistance to vemurafenib.

The findings published in Oncotarget notes that the BRAF gene’s mutation activates PTC that vemurafenib neutralizes selectively.

Despite the early progress with vemurafenib in treating PTC, drug resistance creeps in the later phase making cancer grow and spread further.

The study’s principal author, Carmelo Nucera, who is an assistant professor at Harvard Medical School said the findings have discovered that a combined drug therapy involving vemurafenib and palbociclib could make a viable therapeutic impact on the PTC patients.

Listen: https://www.stitcher.com/podcast/oncotarget

A New Partnership with Cancer Treatment Centers of America

Did you know that Cancer Treatment Centers of America has recently partnered with Web M.D.? Information wins the day, and as a result, CTCA and Web M.D. have partnered together to ensure that patients get the best of both worlds. Cancer is tough disease, but learning how to better care for yourself or a loved on should not be tough. The goal is to help individuals learn as much as they can about cancer and the latest research and information available to them today.

The time of diagnosis is life changing. When an individual hears that they have cancer, the research begins along with planning on every level. The diagnosis, treatment, and the surrounding that patients have is critical to the outcome of their disease. Those who do survive are the most positive and have the most loving and encouraging environment. CTCA was started and designed to help patients fight on all levels. This is why CTCA helps patients address their physical need for healing along with their spiritual man as well.

The focus for CTCA is to provide state-of-the-art technologies, while Web M.D. is focused on providing the latest research in cancer. There are many who seek advanced options and are researching for information pertaining to studies, as well as the outcome and hope for those who choose new therapies. Whether you are using chemotherapy and radiation or you desire to work with doctors that can give you a combination of conventional and holistic therapies, you are in good hands with CTCA and Web M.D.

To Learn More : www.myctca.com

How Dr. Clay Siegall of Seattle Genetics is helping Cancer Patients through Target Cancer Therapies

Dr. Clay Siegall is a scientist who focuses on targeted cancer therapies. He graduated from George Washington University with a Ph.D. in Genetics. In 1998, he co-founded Seattle Genetics. He founded the company to help cancer patients get better treatment options. A family member of his had cancer and he understood the difficulties associated with cancer treatment. He got the motivation to find ways of offering better and advanced treatment. The biotechnology company develops new antibody-based therapies to help in cancer treatment. Dr. Siegall is the company’s President, Chairman, and CEO. The firm does proper research to develop drugs that can help cancer patients.

The company is a leading producer of antibody-drug conjugates (ADCs). FDA approved its first product, ADCetris, in 2011. Before founding his own business, he plied his trade with Bristol-Myers Squibb Pharmaceutical Research Institute for six years. Before that, he worked at the National Institute of Cancer from 1988 to 1991. Dr. Siegall is also a renowned author with several publications to his name. He is a Director at Ultragenyx Pharmaceutical and Alder BioPharmaceuticals.

Dr. Siegall has helped the Seattle Genetics generate millions of dollars with him at the helm. He has guided the firm from a tiny group with a few researchers to a powerhouse in the field of oncology research. The business gets money from the sale of drugs. The Food and Drug Administration currently approves of three indications for ADCetris. Getting an FDA approval is no mean achievement since it only comes after a very long and expensive process. FDA approves only 1 out of 10 candidate drugs Dr. Siegall believes that getting their drugs FDA approved has played a significant role in maximizing profits for Seattle Genetics.

Though Dr. Clay Siegall agrees that the firm has seen some downs, including shrinking capital, and high costs incurred in research and drug development, he insists the company’s strength lies in its employees. The firm has invested in qualified and experienced sales staff. Their job is basically to avail Seattle Genetics’ unique products to the people in need. Dr. Siegall is a staunch believer in hard work and passion in whatever you do, which he says, has made Seattle Genetics very successful.

Clay Siegall – Professional Acumen for Medicine, Science, and Investment

Clay Siegall has several professional acolades behind his name. He holds a B.S. degree from George Washington University in Zoology and a Ph.D. in Genetics from the University of Maryland. Furthermore, Dr. Siegall is published in over 70 papers and journals, has 15 patents and is active in the field of research in targeted therapies for cancer treatment.

Prior to co-founding the biotech company Seattle Genetics in 1998, Dr. Siegall worked in areas of research with The National Cancer Institute and Bristol-Myers Squibb. Presently, Dr. Siegall is nearing two decades in leadership capacity with Seattle Genetics. He is Chairman of its board, Chief Executive Officer and company President. Dr. Siegall too, has aided the company in capital fund raising since its inception. The company financially stands at the brink of being a key player in the cancer treatment industry from its partnerships and its financial status.

In a recent interview, Dr. Siegall told  that  Seattle Genetics earns its income by (1) Selling the drugs it develops; (2) Production partnerships; (3) Licensing of technologies developed in-house.

Dr. Clay Siegall admits sporadic speculative moments during the first couple years of the company’s existence. However, a talented sales staff and unique product line were combined to help solidify the company’s identity and future. Dr. Siegall attributes the company’s marketing success to be due to hard work. He sees education, background, and one’s connections as secondary. He credits work habit and focus are the components that make for success. Unique to Seattle Genetics is the approach to take perspective patrons out for dinner and engage in intense negotiation.

In the recent past Dr. Siegall received awards for his contributions to the fields of medicine and science.

– The University of Maryland Alumnus of the Year Award; he was recognized for his contributions to Math, Computers and Natural Sciences, 2013.

– Pacific Northwest Ernst and Young Entrepreneur of the Year, 2012.

Dr. Siegall continues to be actively involved in promoting targeted therapies for treating cancer and was instrumental in the FDA approving Adcetris in 2011. He foresees a time nearing when targeted therapies will supplant systemic chemotherapy.